You are here

  • Home
  • Archive
  • Volume 9, Issue 12
  • Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

 

Online download statistics by month:

Online download statistics by month: December 2021 to March 2023

AbstractFullPdf
Dec 2021488492190
Jan 202222124169
Feb 202212413048
Mar 202210510653
Apr 2022757718
May 2022686836
Jun 2022818333
Jul 202212513147
Aug 20229910121
Sep 202215916246
Oct 202214614643
Nov 2022868954
Dec 2022979826
Jan 202310810929
Feb 2023868825
Total20682121738